BioLife Solutions (BLFS) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $23.9 million, up 30% year-over-year, driven by strong cell processing demand and new customer acquisitions in evo and Thaw products.

• Adjusted EBITDA margin expanded to 24%, reflecting operating leverage from strategic initiatives and organizational streamlining.

• Net loss from continuing operations narrowed to $0.4 million from $3.2 million in Q1 2024, reflecting improved operating performance.

• The company maintains a robust balance sheet with $107.6 million in cash, cash equivalents, and marketable securities as of March 31, 2025.

• Panthera Cryo Solutions was acquired in April 2025, enhancing the biopreservation portfolio and scientific capabilities.

Financial highlights

• Product revenue rose 33% year-over-year to $22.3 million; cell processing products up $5.4 million, evo and Thaw up $0.2 million.

• GAAP gross margin was 63%, and adjusted gross margin was 66%, both consistent with the prior year.

• GAAP operating loss improved to $1.2 million from $3.3 million in Q1 2024; adjusted operating income was $900,000 versus a $2.4 million loss last year.

• GAAP net loss narrowed to $400,000 ($0.01/share) from $3.2 million ($0.07/share) in Q1 2024.

• Adjusted EBITDA rose to $5.7 million (24% of revenue) from $2.6 million (14% of revenue) year-over-year.

Outlook and guidance

• Full-year 2025 revenue guidance reaffirmed at $95.5–$99 million, with 16–20% overall growth expected.

• Cell processing platform projected to contribute $86.5–$89 million (18–21% growth); evo and Thaw platform to add $9–$10 million (3–15% growth).

• Adjusted gross margin expected in the mid-60s; adjusted EBITDA margin expansion anticipated.

• Management expects current liquidity to be sufficient for at least the next twelve months and the foreseeable future.

• No material revenue expected from Panthera in 2025; $1 million in incremental R&D expenses from the acquisition.